

INDEX

Volume Nine January through December 1975

DRUG INTELLIGENCE AND CLINICAL PHARMACY

January	Pages 1 - 60
February	Pages 61 - 116
March	Pages 117 - 172
April	Pages 173 - 228
May	Pages 229 - 284
June	Pages 285 - 340

July	Pages 341 - 396
August	Pages 397 - 468
September	Pages 469 - 532
October	Pages 533 - 580
November	Pages 581 - 628
December	Pages 629 - 684

A

Acidosis, phenformin-induced, 236
 Actinomycin D, malignant melanoma, pharmacokinetics (ab) 579
 Addition, treatment, 638
 β -Adrenergic Blockade, in essential hypertension (ab) 335
 Adriamycin IV, alopecia (ab) 113; stomatitis (ab) 113; vulvitis (ab) 113
 Adverse Drug Reactions, 648
 adriamycin IV, melanotic reaction (ab) 113; stomatitis (ab) 113; vulvitis (ab) 113
 alkylating agents, myeloma and leukemia (ab) 214
 alprenolol, reduction of deaths (ab) 58
 aminophylline, asthma (ab) 57
 analgesic abuse, renal disease (ab) 331
 anti-anxiety drugs, 26
 antibiotics, pseudomembranous colitis (ab) 278
 anticoagulants, hemorrhage-breast necrosis (ab) 392
 anticonvulsant therapy, osteomalacia (ab) 624; rickets (ab) 669
 antineoplastic agents, 126
 antipsychotic drugs, 536
 aspirin, angioedema (ab) 464; urticaria (ab) 464; effects on fetus (ab) 393; renal disease (ab) 331
 atropine, myocardial infarctions (ab) 393
 azathioprine, chromosomal abnormalities (ab) 393
 Benadryl® (ab) 113
 Bendectin®, fatal overdose (ab) 528
 bupropion, fatal paralytic ileus (ab) 465
 bromide intoxication, fetal central nervous system depression (ab) 465
 busulfan, endocardial fibrosis (ab) 215
 caffeine, anxiety neurosis (ab) 331
 cephalothin, nephrotoxicity (ab) 624
 chloridiazepoxide, death (ab) 393; malformations (ab) 393
 chloroquine poisoning, death (ab) 392; fatality in children (ab) 465
 chlorpromazine (ab) 114
 cigarette smoking, effects on fetus (ab) 393
 clindamycin, pseudomembranous colitis (ab) 278
 clinical pharmacy case studies, 190
 clofibrate, Cushing's syndrome (ab) 577;
 ointment, generalized pustular psoriasis (ab) 528; pituitary-adrenal suppression (ab) 577
 codeine, renal disease (ab) 331
 corticosteroid therapy (ab) 331
 cost, 257
 cyclophosphamide, chromosome abnormalities (ab) 333
 cytotoxic chemotherapy, long-term complications (ab) 164
 dexamethasone nasal spray, abuse of (ab) 163
 diazepam, asthma (ab) 278
 Dilantin®, intravascular coagulation, purpura fulminans (ab) 669
 diphenylhydantoin, choreoathetosis (ab) 58; fetal abnormalities (ab) 333
 disulfiram, organic brain syndrome (ab) 163
 drug induced hemolytic anemia (ab) 277;
 lupus-like syndrome (ab) 278
 drug withdrawal in newborns (ab) 214
 editorial, 321, 382
 ferrous succinate (ab) 112
 gold chrysotherapy, in Sjogren's Syndrome (ab) 164
 gold injections, thrombocytopenia (ab) 278
 haloperidol, dyskinesia (ab) 163; limb malformations (ab) 164; lithium carbonate, brain damage (ab) 58
 halothane, postoperative effect on liver enzymes (ab) 392; SGOT level increase (ab) 464
 heparin, thrombocytopenia (ab) 333
 heroin, withdrawal in neonates (ab) 528
 hexachlorophene, neurotoxicity (ab) 332
 hydantoin, fetal syndrome (ab) 669

hydrocortisone, anaphylactic reaction (ab) 331
 Inderal (letter) 455
 iodide, iodification (ab) 113
 iodine, goiter (ab) 112; hyperthyroidism (ab) 112
 lithium, 17; flu-like syndrome (ab) 332;
 heart failure (ab) 163; multifocal myoclonus (ab) 332
 lithium carbonate, haloperidol, brain damage (ab) 58
 Lomotil® overdose (ab) 114
 lupus-like syndrome (ab) 278
 mandrax overdose, peripheral neuropathy (ab) 577
 melphalan, myelomonocytic leukemia (ab) 214
 meprobamate, death (ab) 393; malformations (ab) 393
 methadone withdrawal, fetal stress (ab) 465;
 in neonates (ab) 528
 methyldopa, hemolytic anemia (ab) 277
 methylprednisolone, anaphylactic reaction (ab) 331
 monitoring, 80
 nitrofurantoin, hepatic injury (ab) 278
 novobiocin-tetracycline, pseudomembranous colitis (ab) 278
 oral contraceptives, breast cancer (ab) 464;
 intracranial venous thrombosis (ab) 163;
 myocardial infarction (ab) 527, 528; stroke (ab) 393
 penicillamine, Goodpasture's Syndrome (ab) 464
 penicillin, hemolytic anemia (ab) 277, 577;
 pseudomembranous colitis (ab) 278
 pharmacist's role, 12
 phenacetin, renal disease (ab) 331
 phenformin, lactic acidosis (ab) 236
 phenothiazines, fatal paralytic ileus (ab) 465
 potassium iodine, cardiac irritability (ab) 113
 propoxyphene overdose (ab) 113
 propylthiouracil, liver disease (ab) 215
 prostaglandin F₂, alpha, pregnancy termination (ab) 331
 quinidine, hemolytic anemia (ab) 277
 salicylic acid, percutaneous absorption (ab) 624
 sodium warfarin, ecchymosis (ab) 392
 steroids, peliosis hepatis (ab) 114
 succinylcholine, hypoventilation (ab) 214
 sulfamethoxazole, allergic reaction, 660
 tannic acid, hepatotoxicity (ab) 115
 thiethixene, hyponatremia (ab) 279
 tolbutamide, inotropic effects (ab) 214
 trimethadione, fetal syndrome (ab) 669
 vincristine, increased secretion of ADH (ab) 394
 vinyl-chloride, liver disease (ab) 278
 vitamin E, coagulopathy (ab) 58
 warfarin, hemorrhage-breast necrosis (ab) 392
 Aikman, Jane (author) book review, 389
 Alcohol, drug abuse, 300, 370; drug interactions (ab) 670; interaction with amitriptyline (ab) 527, with chloridiazepoxide (ab) 623, with chlorimipramine (ab) 527, with diazepam (ab) 623, with doxepin (ab) 527, with nortriptyline (ab) 527, with placebo (ab) 527, with thioridazine (ab) 623
 Alexander, Michael M. (author) abstracts, 57, 112, 113, 114, 162, 163, 164, 213, 214, 215, 217, 277, 278, 279, 280, 331, 332, 334, 335, 394, 466, 624, 671; letter concerning error in digoxin dose in December 1974 article, 154
 Alkylating Agents, adverse reaction (ab) 214
 Allen, Marcia D. (co-author) Role of Nurse and Pharmacist Monitors in the Boston Collaborative Drug Surveillance Program, 648
 Allerest, interaction with amphetamine (ab) 57
 Allergic Reactions, tartrazine, 198
 Alprenolol, reduction of deaths (ab) 58
 Amantadine, interaction with ketamine anesthesia (ab) 213

American Institute of the History of Pharmacy, assistance to Bicentennial speakers (letter) 570
 American Pharmaceutical Association, roles, 406
 American Society of Hospital Pharmacists, new goals for (letter) 101; roles, 406
 Aminophylline, asthma (ab) 57
 Aminopyrine Metabolism, assessment of (ab) 279
 Amitriptyline, interaction with alcohol (ab) 527
 Amphetamine, interaction with Allerest (ab) 57;
 with Contac (ab) 57
 Ampicillin, in haemophilus influenza meningitis (ab) 394
 Analgesics, nephropathy (ab) 331
 Angaran, David M. (author) My Son, the Clinical Pharmacist, 298; A White Coat, Name Tag and Beeper, 566; (ed) The Exports, 204
 Analgesic Abuse, renal disease (ab) 331
 Antacids, decubitus ulcers (letter), 54
 Anti-anxiety Drugs, interactions, 26
 Antibiotics, batch certification and bioequivalence (ab) 578; penetration into sputum (ab) 164; prophylactic, vaginal hysterectomy (ab) 165; pseudomembranous colitis (ab) 278; utilization (letter) 155
 Anticoagulants, hemorrhage-breast necrosis (ab) 392
 Anticonvulsant Therapy, adverse reaction (ab) 669; osteomalacia (ab) 624
 Antineoplastic Agents, and fever, 126
 Antipsychotic Drugs, interactions, 536
 Areas Below Plasma Concentration Time-Curves, an equation for (ab) 625
 Arkwright, Thomas W. (author) abstracts, 214, 394
 Aspirin, adverse effects on fetus (ab) 393; angioedema (ab) 464; urticaria (ab) 464; interaction with heparin (ab) 162; intoxication, 350; myocardial infarction (ab) 115; renal disease (ab) 331; See also Salicylates
 Atropine, myocardial infarctions (ab) 393; PGF₂ α -induced bronchoconstriction (ab) 529
 Audiovisual Aids, use in patient counseling, 485
 Azathioprine, chromosomal abnormalities (ab) 393; comparison in myeloma (ab) 216

B

Bacterial Meningitis, case study, 242; comment and author response (letters) 457
 Bacteroides Infections, metronidazole in (ab) 279
 Barger, Robert C. (author) letter concerning adsorption of insulin in protein solutions, 664
 Barto, Mary H. (author) Dantrolene Sodium Evaluation, 42
 Baugher, Donald R. (author) Community Pharmacy Practice in the Year 2000, 420
 Belcastro, P. F. (author) letter concerning clinical and traditional pharmacy practice, 568
 Benadryl®, withdrawal in newborn (ab) 113
 Bendectin®, fatal overdose (ab) 528
 Bender, Kenneth J. (author) Salicylate Intoxication, 350
 Benzodiazepines, interactions, 26
 Benzotripine, and phenothiazines, fatal paralytic ileus (ab) 465
 Benzyl Alcohol, toxicity of (letter) 154
 Bergman, H. David (author) Prescribing of Drugs in a Nursing Home, 365
 Betker, Rita M. (author) letter concerning editorial about tartrazine, 568
 Billingsley, Len A. (author) letter concerning gentamicin overdosage, 618
 Bioavailability, evaluating (letter) 55
 Biopharmaceutics, 501; of dantrolene, 42; See also Pharmacokinetics
 Black, Curtis D. (co-author) Potential Drug Interactions—Fact or Fallacy?, 586
 Boards of Pharmacy, roles, 406
 Bodendorfer, Thomas W. (author) letter concerning pharmacy's quest for professional direction, 206

Bodner, Benjamin M. (author) letter concerning antibiotic utilization, 155

Bollinger, R. O. (co-author) Isolation, Propagation, Freeze Preservation and Studies of Drug Sensitivity of *Toxoplasma gondii* in Human Tissue Culture, 264

Books Reviewed

Applied Therapeutics for Clinical Pharmacists (L. Y. Young and M. A. Kimble), 460

Assessment of the Carcinogenicity and Mutagenicity of Chemicals (WHO Scientific Group), 211

The Bioavailability of Drug Products (American Pharmaceutical Association), 572

Bioavailability of Drugs: Principles and Problems (WHO Scientific Group), 210

The Biological Imperatives: Health, Politics and Human Survival (A. Chase), 104

Bugs and Drugs, Volume 3 (J. H. Mulholland, et al.), 461

Drug Abuse in Industry (J. M. Scher), 574

Drug Interactions and Their Mechanisms (I. H. Stockley), 460

Drug Therapy of Cancer (G. Brulé, S. J. Eckhardt, T. C. Hall, & A. Winkler), 210

Drug Treatment in Intestinal Helminthiasis (A. Davis), 460

Drugs and Athletic Performance (M. H. Williams), 523

Drugs and the Developing Brain (A. Vernadakis and N. Weiner), 522

The Etiology of Alcoholism (J. B. Roebuck and R. G. Kessler), 389

Index Nominum 1975/76 (Laboratory of the Swiss Pharmaceutical Society in Zurich), 522

The National Formulary XIV (National Formulary Board of Trustees), 389

Pediatrics - 15 (H. L. Barnett, A. H. Einhorn), 103

Pharmaceutical Calculations, 6th ed (M. J. Stoklosa), 105

Pharmacodynamics and Patient Care (M. P. Johns), 574

Pharmacy, Drugs and Medical Care (M. C. Smith and D. A. Knapp), 461

The Physician's Assistant: Today and Tomorrow (A. M. Sadler, B. L. Sadler, A. A. Bliss), 103

Plastic Containers for Pharmaceuticals - Testing and Control (J. Cooper), 102

Pocket Consult, Antiepilepsy Agents (M. J. Reilly), 572

Principles and Techniques of Human Research and Therapeutics - Volume IV, Importance of Experimental Design and Biostatistics (F. G. McMahon), 572

Principles of Medicinal Chemistry (W. O. Foye), 212

Progress in Medicinal Chemistry, Volume II (G. P. Ellis and G. B. West), 573

Psychosocial Pharmacy: The Synthetic Society (F. B. Gable), 104

Sterile Dosage Forms: Their Preparation and Clinical Application (S. Turco and R. E. King), 212

WHO Expert Committee on Drug Dependence: Nineteenth Report (World Health Organization Technical Report Series), 211

WHO Expert Committee on Drug Dependence: Twentieth Report (World Health Organization Technical Report Series), 102

Born, Emelie S. (author) letter concerning clinical pharmacology - clinical pharmacy seminar, 276

Bosso, John A. (author) Bacterial Meningitis, 242; Pneumocystis Carinii Pneumonia Treated with Pentamidine, 657; letter replying to comments on Bacterial Meningitis article, 457; (co-editor) Pediatric Clinical Pharmacy Case Studies, 242, 657

Bowman, John D. (author) letter concerning Cost Effectiveness Comparison article, 517

Bradberry, J. Chris (ed) Responsibility of Practice, 383

Brand Name and Generic Prescriptions, consumer price differentials (ab) 222

Brannon, Joanne B. (author) book reviews, 104, 105

Bromide Intoxication, fetal CNS depression (ab) 465

Bryan, Candace K. (ed) Pharmacy's Private Practitioner, 513

B.Sc. and Pharm.D., one or two degrees? (letter), 569

Bumetanide, in pulmonary edema (ab) 216

Burkhardt, Vincent dePaul (co-author) Technical and Theoretical Aspects of Patient Counseling Using Audio Visual Aids, 485

Busulphan, endocardial fibrosis (ab) 215

C

Caffeine, anxiety neurosis (ab) 331

Calcitonin-Salmon, evaluation, 557

Calcium Gluconate, interaction with potassium citrate (ab) 466

Cancro, Robert (co-author) A Course in Psychotropic Drug Therapy for First-Year Psychiatry Residents, 316

Carbamazepine, pharmacokinetics (ab) 529

Carbenicillin Therapy, normal and impaired renal function (ab) 579

Cardoni, Alex A. (co-author) A Course in Psychotropic Drug Therapy for First-Year Psychiatry Residents, 316

Cargille, Charles M. (author) Carrying Capacity, Population & the Quality of Life, 36

Case Studies, salicylate intoxication, 350

Catheters, contamination, 76

Cefazolin, kinetics in renal failure and dialysis (ab) 670

Cephaloridine, in bacterial meningitis (ab) 395

Cephalothin, in bacterial meningitis (ab) 395; nephrotoxicity (ab) 624; by venous catheter (ab) 165

Chan, Peter W. (author) letter concerning use of antacids for decubitus ulcers, 54

Charcoal, management of poisoning with (ab) 334

Chaussade, J. (author) letter concerning polyvinyl chloride plastics for IV use, 518

Chloral Hydrate, interaction with furosemide (ab) 466

Chlorambucil, comparison in myeloma (ab) 216

Chloramphenicol, interaction with cyclophosphamide (ab) 624

Chlordiazepoxide, death (ab) 393; interaction with alcohol (ab) 623, with diazepam (ab) 623, with thioridazine (ab) 623; malformations (ab) 393

Chlorimipramine, interaction with alcohol (ab) 527

Chlorodyne, dependence (ab) 223

Chloroprocaine, paracervical block with (ab) 280

Chloroquin, intestinal amebiasis (letter) 569

Chloroquine Poisoning, death (ab) 392; fatality in children (ab) 465

Chlorpromazine, adverse reaction (ab) 114; interaction with orphenadrine (ab) 623, with phenobarbital (ab) 623

Cholesterol, plasma, effect of oral contraceptives (ab) 670

Chudzik, Gregory M. (co-editor) Pediatric Clinical Pharmacy Case Studies, 242, 657

Cigarette Smoking, adverse effects on fetus (ab) 393

Cirrhosis, elimination of clindamycin (ab) 466

Clindamycin, elimination in cirrhosis (ab) 466; pseudomembranous colitis (ab) 278; renal impairment (ab) 334; treatment of skin infections (ab) 217

Clinical Pharmacology, clinical pharmacy seminar (letter) 276

Clinical Pharmacist's Roles, 12, 480, 485, 566, 638, 648; drug monitoring, 80; educational, 316; future, 406, 426, 439; pain conditioning, 68; patient education, 601; primary care, 129; satire, 298; letter praising satire, 457

Clinical Pharmacy

clinical pharmacology seminar (letter) 276

cost justification, 257

dilemma of (letter) 54; possible solution (letter) 55

education, rise and fall (ed) 97; education, future, 447

legal aspects, 124

pharmacist-physician coordination, 86

and physicians, 129

practice, 606; editorial, 321; the experts (ed) 204; hospital rounds (ed) 270; "pharmacists' syndrome" (ed) 151; quest for professional direction (ed) 45; strategy for hard times (ed) 204; and traditional services (ed) 151, (letter) 328

practice in year 2000, 406; community, 420; educational needs, 447; impact of computers, 439; impact of technicians, 430; impact of technologists, 434; possible determinants of practice, 426; women, 412, 415

principles, 12

satire, A White Coat, Name Tag and Beeper, 566

residents, state licensure (ed) 97

service, 553; patient education (ed) 322; service—who needs it? (ed) 323

strategy for hard times (ed) 204

vs. Traditional Practice (letters) 329, 568

Clinical Pharmacy Case Studies, adverse drug reactions, 190; bacterial meningitis, 242; peptic ulcer, 86; pneumocystis carinii pneumonia treated with pentamidine, 657

Clobetasol, Cushing's syndrome (ab) 577; ointment, generalized pustular psoriasis (ab) 528; pituitary-adrenal suppression (ab) 577

Clonidine Hydrochloride, A.M.A. evaluation of (ab) 578

Cloyd, James (co-author) A Self-Instructional Learning Package About Parenteral Hyperalimentation for Students of Nursing, Pharmacy and Medicine, 493

Coats, Eugene A. (author) book review, 573

Codeine, renal disease (ab) 331

Cohen, Monte S. (author) Tartrazine Revisited, 198; letter, addendum to tartrazine article, 330

Communications, verbal, of community pharmacists (ab) 622

Community Pharmacy, conclusions and recommendations (ab) 622; education and roles (letter) 618; future, 420; pharmacist's professional opportunity (ed) 514; practice in year 2000 (ed) 454; verbal communications of pharmacists (ab) 622

Competency of Practitioners, 426, 591

Compliance, patient (ed) 268

Compounding Accuracy, 591

Computers, future use, 439; patient monitoring (letter) 516

Contact, interaction with amphetamine (ab) 57

Contamination, IV and catheter, 76

Continuing Education, drug therapy course (letter), 276; open university in Tennessee (letter), 101; quiz, 180

Cooper, Jack (author) letter concerning polyvinyl chloride plastics for IV use, 519

Corticosteroid Therapy, anaphylaxis-like reactions (ab) 331

Cost Effectiveness Comparisons, 257; comment and author reply (letters) 517, 518

Cost Justification, clinical pharmacy, 257

Courts, future roles, 426

Covinsky, Joel O. (ed) "Pharmacists' Syndrome", 151

Cryptococcal Meningitis, flucytosine, 180

Cyclophosphamide, chromosome abnormalities (ab) 333; interaction with chloramphenicol (ab) 624, with sulfaphenazole (ab) 624

Cytarabine (ab) 395

Cytotoxic Chemotherapy, long-term complications (ab) 164

D

D-1-T, investigational drug, 655

Dantrium, See Dantrolene Sodium

Dantrolene Sodium, evaluation, 42; treatment of spasticity (ab) 334

Darvon, positive results for methadone screening (letter) 515

Davis, Larry J. (author) Drug Evaluation Data, Ibuprofen, 501; letter concerning lidocaine in myocardial infarction, 275

Deans, and professional degrees (ed) 205, (letters) 330, 515

Degrees, B.Sc. and Pharm.D. (letter) 569; professional, and deans (ed) 205, (letters) 330, 515; professional, vs. self-education (letter) 100

de Haen, Paul (author) The Drug Lag - Does it Exist in Europe?, 144; New Products 1973-1974, U.S.A., 504; reply to Bruce Fisher concerning his cards, 684

DeLattre, Mary (author) letter concerning heparin strengths, 387

Dencker, Lennart (author) book review, 522

Dexamethasone Nasal Spray, abuse of (ab) 163

Dextroamphetamine, interaction with Contac (ab) 57; interaction with Allerest (ab) 57

Diabetes Mellitus, nurse practitioner in the management of patients with (ab) 222

Diabetic Ketoacidosis, therapy, 135

Diaz Rounds, 190

Diazepam, asthma (ab) 278; interaction with alcohol (ab) 623, with chlordiazepoxide (ab) 623, with thioridazine (ab) 623; placental transfer (ab) 579; thioridazine as an alternate (ab) 335

Dick, M. Lawrence (co-author) A Cost Effectiveness Comparison of a Pharmacist Using Three Methods for Identifying Possible Drug Related Problems, 257; (author) reply to comment on article, 518

DICP and community practitioners (letter) 207

Diet, in ketoacidosis, 135

Digitoxin, metabolism and excretion (ab) 59

Digoxin, error in dose in December 1974 article (letter) 154; intoxication, salivary levels as an indicator (ab) 671; serum levels (letter) 274

Dilantin®, adverse reaction (ab) 669

Dilemma of Clinical Pharmacy (letter) 54; possible solution (letter) 55

Diodoquin®, intestinal amebiasis (letter) 569

Diphenhydramine, overdose, peripheral neuropathy (ab) 577

Diphenylhydantoin, choreoathetosis (ab) 58; dosage (letter) 274; fetal abnormalities (ab) 333; pulmonary function loss (ab) 165

Diplococcus pneumoniae, 242

Disulfiram, organic brain syndrome (ab) 163

Dopamine, shock therapy (letters) 456, 665

Doxepin, interaction with alcohol (ab) 527

Driperidol, cardiovascular effects (ab) 217

Drug Abuse, 249; education, untoward effects of (ab) 223; origin and prevention, 300; patient-authorized refills, 489; prevention, 370; traffic accidents, 370; treatment, 638

Drug Actions, Interactions and Reactions, 57, 112, 162, 213, 277, 331, 392, 464, 527, 577, 623, 669

Drug Compounding, accuracy, 591

Drug Dependence, 638; WHO Report, Part I, 249; Part II, approaches to prevention, 300; Part III, conclusions and recommendations, 370

Drug Dosage, estrogen (ab) 165; flucytosine, 180

Drug Evaluation Data, Calcitonin-Salmon, 557; Dantrolene, Sodium, 42; Ibuprofen, 501; Sodium Nitropruside, 361

Drug History, 80

Drug-Induced Illness, pharmacist's role, 12; hemolytic anemia (ab) 277; lupus-like syndrome (ab) 278

Drug Information, indexing and abstracting services, 190; techniques, 190

Drug Information Centers, role in formulary revision, 596

Drug Interactions, 536, 586
 alcohol (ab) 670; amitriptyline (ab) 527; chlordiazepoxide (ab) 623; chlorimipramine (ab) 527; diazepam (ab) 623; doxepin (ab) 527; nortriptyline (ab) 527; placebo (ab) 527; thioridazine (ab) 623
 Allerst-amphetamine (ab) 57
 amantadine-ketamine anesthesia (ab) 213
 amitriptyline-alcohol (ab) 527
 amphetamine-Allerst (ab) 57; Contac (ab) 57
 anti-anxiety drugs, 26
 antipsychotic drugs, 536
 aspirin-heparin (ab) 162
 barbiturates-anticoagulants, 589; griseofulvin, 589
 benzotropine-phenothiazines (ab) 465
 calcium gluconate-potassium citrate (ab) 466
 chloral hydrate-furosemide (ab) 466
 chloramphenicol-cyclophosphamide (ab) 624; anticoagulants, 589
 chlordiazepoxide-alcohol (ab) 623; diazepam (ab) 623; thioridazine (ab) 623
 chlorimipramine-alcohol (ab) 527
 chlorpromazine-orphenadrine (ab) 623; phenobarbital (ab) 623
 cholesterol, plasma-oral contraceptives (ab) 670
 cholestyramine-thyroid, 587
 clindamycin, cirrhosis (ab) 466
 CNS drug interactions, antipsychotics, 536
 Contac-amphetamine (ab) 57
 cyclophosphamide-chloramphenicol (ab) 624; sulfaphenazole (ab) 624
 diazepam-alcohol (ab) 623; chlordiazepoxide (ab) 623; thioridazine (ab) 623
 doxepin-alcohol (ab) 527
 editorial, 269
 ephedrine-theophylline (ab) 527
 ethacrynic acid-warfarin (ab) 213
 furosemide-chloral hydrate (ab) 466
 gallamine-morphine (ab) 277; nitrous oxide (ab) 277; oxygen anesthesia (ab) 277; tubocurarine (ab) 277
 heparin-aspirin (ab) 162
 hepatic drug metabolizing enzymes-phenobarbital (ab) 623
 hydroxyzine-theophylline (ab) 527
 hyperbaric oxygen and drugs (letter) 276
 ketamine anesthesia-amantadine (ab) 213
 laboratory tests, 26
 levodopa-papaverine (ab) 214
 methylthiothiazide (ab) 577
 minoxidil-propranolol (ab) 162
 morphine-gallamine (ab) 277; pancuronium (ab) 277; propranolol (ab) 277; pancuronium (ab) 277
 nortriptyline-alcohol (ab) 527
 oral contraceptives-plasma vitamins, cholesterol and triglycerides (ab) 670
 orphenadrine-chlorpromazine (ab) 623
 oxygen anesthesia-gallamine (ab) 277; pancuronium (ab) 277
 pancuronium-morphine (ab) 277; nitrous oxide (ab) 277; oxygen anesthesia (ab) 277; tubocurarine (ab) 277
 papaverine-levodopa (ab) 214
 penicillin-neomycin, 587
 phenformin-vitamin B₁₂ (ab) 162
 phenobarbital-chlorpromazine (ab) 623; hepatic drug metabolizing enzymes (ab) 623; vitamin D (ab) 670
 phenothiazines-benzotropine (ab) 465; and antacids, 589
 placebo-alcohol (ab) 527
 potassium citrate-calcium gluconate (ab) 466
 potential drug interactions - fact or fallacy, 586
 propranolol-minoxidil (ab) 162; morphine (ab) 277
 pseudoephedrine-triprolidine (ab) 213
 psychotherapeutic drugs, 536
 rifampin-warfarin (ab) 466
 spironolactone-urinary pH (ab) 57
 sulfaphenazole-cyclophosphamide (ab) 624
 theophylline-ephedrine (ab) 527; hydroxyzine (ab) 527
 thiazide-methylthio (ab) 577
 thioridazine-alcohol (ab) 623; chlordiazepoxide (ab) 623; diazepam (ab) 623
 triglycerides, plasma-oral contraceptives (ab) 670
 triprolidine-pseudoephedrine (ab) 213
 tubocurarine-gallamine (ab) 277; pancuronium (ab) 277

urinary pH-spironolactone (ab) 57
 vitamin B₁₂-phenformin (ab) 162; malabsorption (ab) 466
 vitamin D-phenobarbital (ab) 670
 vitamins, plasma-oral contraceptives (ab) 670
 warfarin-ethacrynic acid (ab) 213; rifampin (ab) 466

Drug Lag, 144

Drug Marketing, lag in, 144

Drug Monitoring, See Drug Utilization

Drug Products, tartrazine-containing, 198

Drug Sensitivity, of Toxoplasma gondii, 264

Drug Services, contrasting approaches to (ab) 223

Drug Surveillance, See Drug Utilization

Drug Therapy, 606; arthritis, 501; chronic spasticity, 42; clinical pharmacist's roles, 12, 406; continuing education course (letter) 276; cryptococcal meningitis, 180; detoxification, poly drug abuse, 638; diabetic ketoacidosis, 135; effectiveness, 292; new drugs 1973/1974, 504; of pain, 68; problems in hospitals, 80; psychotropic, 316; rational, 480; salicylate intoxication, 350

Drug Use Control, See Drug Utilization

Drug Utilization, appropriate, 292; case study, 86; clinical pharmacist's role, 80; clinical pharmacy residencies, 606; computers, 439; nursing homes, 365; overprescribing, 480; PSROs, 553, 648

Durham-Humphrey Amendment, 489

E

Editorial Advisory Board (ed), 45

Editorials
 David M. Angaran, The Experts, 204
 J. Chris Bradberry, Responsibility of Practice, 383
 Candace K. Bryan, Pharmacy's Private Practitioner, 513
 Joel O. Covinsky, Pharmacists' Syndrome, 151
 Donald E. Francke, The Community Pharmacist's Professional Opportunity, 514; Editorial Advisory Board, 45; The Five-Year Pharm.D., 384; Guidelines for Pharm.D. Programs, 617; Pharmacy in the Year 2000, 454; Population and the Quality of Life, 46; Professional Degrees and Deans, 205; Salute to Women Pharmacists, 663; Temporary State Licensure for Pharmacy Residents, 97
 John T. Frank, Pharmacy's Quest for Professional Direction, 45
 Philip D. Hansten, Adverse Drug Reactions - Do We Really Know?, 321
 Leslie Hendels, Wandering from Bed to Bed, 270
 Hugh N. Lunan, Drug-Drug Interactions, 269; New Developments in Pharmacy - How Does the Institution Meet This Need?, 453
 Don C. McLeod, Strategy for Clinical Pharmacy in Hard Times, 204; The Dilemma in Pharmacy Residency Training, 382
 Paul G. Pierpaoli, The Rise and Fall of Clinical Pharmacy Education, 97
 Robert G. Pietrusko, Clinical Pharmacy Service - Who Needs It?, 323
 L. Kent Porter, The Literature and the Pharmacist, 513
 Randall A. Prince, The Need for Pharmacokinetic Data in Diseased Individuals, 270
 Robert P. Rapp, Patient Oriented Pharmacy Practice - Does it Include Traditional Services?, 151
 Thomas P. Reinders, Patient Education - A Clinical Pharmacy Service, 322
 John A. Romankiewicz, Spanning the Gap - Clinical Research, 324
 Dorothy L. Smith, Why Should Patients Comply with Medication Instructions?, 268
 Ronald B. Stewart, The Fatal Drug-Reaction Debate, 382; What the Pharmacist Needs to Know, 664
 Dianne E. Tobias, Round and Round, 321
 Harvey A. K. Witney, Educating the Public about Drugs, 571; Education and Utilization of Pharmacy Supportive Personnel, 452; The Five-Year Pharm.D., 384

Editor's Reply to comments on editorial (letter) 620

Education
 clinical pharmacy, rise and fall of (ed) 97
 continuing, drug therapy course (letter) 276; open university in Tennessee (letter) 101; quiz, 180
 drug abuse, untoward effects of (ab) 223
 educating the public about drugs (ed) 571
 future, 406; clinical, accreditation, 447
 open university in Tennessee (letter) 101
 patient, 485, 601; a clinical pharmacy service (ed) 322; compliance with medication instructions (ed) 268
 "pharmacists' syndrome" (ed) 151
 pharmacy supportive personnel (ed) 452

Pharm.D. Programs, five-year (ed) 384, letter, 619; guidelines for (ed) 617; list of (letter) 207
 physicians and nurses, 80
 professional degrees, and deans (ed) 205; vs. self-education (letter) 100
 professional literature (ed) 513
 residency training (ed) 382; 606
 role of clinical pharmacist, 316
 residents, teaching and service responsibilities, 606
 What the pharmacist needs to know (ed) 664
 Elliott, Roger K. (author) letter concerning new goals for ASHP, 101
 Emetine, intestinal amebiasis (letter) 569
 Environmental Contamination, population (ed) 46
 Ephedrine, interaction with theophylline (ab) 527
 Epidemiology, 648
 Errors in Compounding, 591
 Eshelman, Fred N. (author) book review, 574
 Estrogen, dosage in post-menopausal osteoporosis (ab) 165
 Ethacrynic Acid, interaction with warfarin (ab) 213
 Evans, William E. (co-author) Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole, 660
 Evens, Ronald P. (author) letter concerning toxicity of intravenous benzyl alcohol, 154
 Excretion, of salicylates, 350

F

Faculty, women, 412
 Family Planning, 36
 Family Practitioner Article, omission of acknowledgement (letter) 54
 Farr, Glen E. (author) letter concerning open university in Tennessee, 101
 Federal Food, Drug and Cosmetic Act, 489
 Fentanyl, cardiovascular effects of (ab) 217
 Ferrous Succinate, adverse drug reaction (ab) 112
 Fertility Control, and the quality of human life (ab) 222
 Fetus, Toxoplasma gondii, 264
 Fever, from antineoplastic agents, 126
 Filters, and phlebitis, 76
 Fink, Joseph L., III (author) letter concerning editorial on professional degrees and deans, 515
 Finn, Andrew (co-author) letter concerning clinical pharmacy practice, 55
 Fisher, Bruce (author) humorous poem about Paul de Haen's cards, 567
 Five-Year Pharm.D. Programs (ed) 384; letter, 619; editorial response, 620
 Flotafenine, comparison with pentazocine (ab) 529
 Flucytosine, pharmacokinetics, 180; See also Fluorocytosine
 Fluids, in salicylate intoxication, 350
 5-Fluorocytosine, and disseminated candidiasis (ab) 115; See also Flucytosine
 Fong, Gary R. (author) The Role of the Pharmacist in an Operant Conditioning Program for Chronic Pain Patients, 68
 Food and Drug Administration, new drugs, 504
 Formulary, hospital, revision, 596
 Formulations, for pain medication, 68
 Francke, Donald E. (editorials) The Community Pharmacist's Professional Opportunity, 514; Editorial Advisory Board, 45; The Five-Year Pharm.D., 384; Pharmacy in the Year 2000, 454; Population and the Quality of Life, 46; Professional Degrees and Deans, 205; Salute to Women Pharmacists, 663; Temporary State Licensure for Pharmacy Residents, 97; (author) letter responding to comments on editorial, 620
 Frank, John T. (ed) Pharmacy's Quest for Professional Direction, 45
 Furosemide, interaction with chloral hydrate (ab) 466

G

Gallamine, interaction with morphine (ab) 277, with nitrous oxide (ab) 277, with oxygen anesthesia (ab) 277, with tubocurarine (ab) 277
 Gallelli, Joseph F. (co-author) Investigational Drug Information, 655
 Gardner, Sue (co-author) The Impact of the Pharmacy Technologist Upon Pharmacy Practice in the Year 2000, 434
 Garrison, Thomas J. (author) letter concerning editorial on five-year Pharm.D., 619
 Catlin, Larry A. (co-author) Investigational Drug Information, 655
 Gelperin, Abraham (author) A Supreme Court Decision Will Require Clinical Pharmacy, 124
 Generic and Brand Name Prescriptions, consumer price differentials (ab) 222
 Genetic Variations, in drug response (ab) 279
 Gentamicin, blood levels, guide to nephrotoxicity (ab) 671; dose regimen of (ab) 394; heparin,

peritoneal dialysis solutions (letter) 388; overdosage (letter) 618; reduction in heparin activity (letters) 568

Gerbracht, Louise (author) letter concerning heparin and gentamicin in peritoneal dialysis solutions, 388; (co-author) letter concerning reduction in heparin activity by gentamicin, 568

Geriatric Patients, prescribing for, 365

Giorgianni, Salvatore J. (author) letter concerning dopamine for shock therapy, 665

Gisendanner, Clarence E. (author) book reviews, 212

Giusti, Donald L. (co-author) *The Pharmacokinetics of Flucytosine in Cryptococcal Meningitis*, 180

Glues, fast-drying, hazards of (letter) 515

Gold Chrysotherapy, in Sjogren's Syndrome (ab) 164

Gold Injections, thrombocytopenia (ab) 278

Gong, William C. (co-author) *Phenformin Induced Lactic Acidosis: A Case Report and Review of the Literature*, 236

Government, future roles, 426

Greenblatt, David J. (co-author) *Role of Nurse and Pharmacist Monitors in the Boston Collaborative Drug Surveillance Program*, 648

Greene, Russell J. (author) *Clinical Pharmacological Aspects of Lithium Therapy*, 17

Griffin, Gerald (author) letter about clinical pharmacy practice, 54

Grimes, George J. (co-author) *Investigational Drug Information*, 655

Group Practice Article, omission of acknowledgement (letter) 54

Guyann, James B., Jr. (author) letter concerning editorial on clinical pharmacy practice, 328

H

Half-Life, of flucytosine, 180

Haloperidol, dyskinesia (ab) 163; limb malformations (ab) 164; lithium carbonate, irreversible brain damage (ab) 58

Halothane, postoperative effect on liver enzymes (ab) 392; SGOT level increase (ab) 464

Hansten, Philip D. (ed) *Adverse Drug Reactions - Do We Really Know?*, 321

Hartshorn, Edward A. (author) *The Antipsychotic Drugs Comprehension Quiz*, 550; book review, 572; *Interactions of CNS Drugs: Psychotherapeutic Agents - The Antianxiety Drugs*, 26; *Interactions of CNS Drugs: Psychotherapeutic Agents - The Antipsychotic Drugs*, 536

Hays, Dennis P. (author) letter concerning evaluation of bioavailability, 55

Health Care Sociology, 156, 222, 622

Hemophilus influenzae, 242

Hendele, Leslie (ed) *Wandering from Bed to Bed*, 270; (author) letter concerning five-year Pharm.D., 619

Hendele, Leslie (ed) *Wandering from Bed to Bed*, 270; (author) letter concerning five-year Pharm.D., 619

Henderson, H. Richard (co-author) *Pharmacy Involvement - Polydrug Detoxification Unit*, 638

Heparin, activity, reduction by gentamicin (letters) 568; bleeding complications, 560; fibrinogen survival in cirrhosis (ab) 579; gentamicin, peritoneal dialysis solutions (letter) 388; interaction with aspirin (ab) 162; thrombocytopenia (ab) 333; variable strengths (letter) 387

Hepatic Drug-Metabolizing Enzymes, interaction with phenobarbital (ab) 623

Heroin, withdrawal in neonates (ab) 528

Hexachlorophene, neurotoxicity (ab) 332

Hirakawa, Paul K. (co-author) *Investigational Drug Information*, 655

Hirschman, Joseph L. (co-author) *PSRO - Participation Pathways for Pharmacists*, 553

Horn, John R. (author) book review, 461; (co-author) *The Pharmacokinetics of Flucytosine in Cryptococcal Meningitis*, 180

Hospital Formulary, revision, 596

Hospital Prescription Blanks, use of (letter) 54

Hospital Rounds, pharmacist's role (ed) 270

Hu, Ada Chung Wai (author) book review, 574

Husley, Stephen C. (co-author) *Activities of the Clinical Pharmacist Practicing in the Office of a Family Practitioner*, 129

Hydantoin, adverse reaction (ab) 669

Hydrocortisone, anaphylactic reaction (ab) 331

Hydroxyzine, interaction with theophylline (ab) 527

Hyperbaric Oxygen, interaction with drugs (letter) 276

Hypertension, monitoring, 420

I

Ibuprofen, evaluation, 501; rheumatoid arthritis (ab) 395

Ignoffo, Robert J. (author) *Incidence of Bleeding Complications in Patients on Intermittent IV Heparin Therapy*, 560

Imhoff, Thomas E. (author) book review, 461

Inderal, adverse reaction (letter) 455

Infections, bacteroides, metronidazole in (ab) 279

Innovare, cardiovascular effects of (ab) 217

Instructions to Authors, 47

Insulin, adsorption in protein solutions (letter) 664; role in metabolism, 135

Intestinal Amebiasis (letter) 569

Intoxication, aspirin, salicylates, 350

Investigational Drug Information, D-1-T, 655; *Lipexal*, 656; *Three-dihydroxyphenylserine*, 655

Iodide, intoxication (ab) 113

Iodine, goiter (ab) 112

Ipecac, in hydrocarbon ingestion (ab) 164

Iron, intoxication (ab) 112

Isopterolol, metabolism in children (ab) 59

IV Therapy, filtration, 76; guidelines for compatibility (letter) 155; parenteral hyperalimentation, 493

J

Jackson, Eric A. (author) abstracts, 115

Jacobs, Richard S. (author) *Drug Evaluation Data - Calcitonin-Salmon*, 557

Jeffrey, Louis P. (author) *Impact of the Pharmacy Technician Upon Pharmacy Service in the Year 2000*, 430

Jelliffe's Computer Program, patient monitoring (letter) 516

Johnson, Curtis (co-author) *A Self-instructional Learning Package About Parenteral Hyperalimentation for Students of Nursing, Pharmacy and Medicine*, 493

Johnston, Timothy S. (author) letter concerning intestinal amebiasis, 569

Jones, Mark (author) abstracts, 115, 163, 164, 277, 333, 393, 466

Juhl, Randy P. (co-author) letter about family practitioner - group practice article, 54

Jusko, William J. (author) letter concerning variable heparin strengths, 387

K

Kanamycin, dose regimen of (ab) 394

Kato, Donald B. (co-author) *Phenformin Induced Lactic Acidosis: A Case Report and Review of the Literature*, 236; (author) letter concerning diphenylhydantoin dosage, 274

Kayser, Steve (co-editor) *The DIAS Rounds*, 190

Ketamine Anesthesia, interaction with amantadine (ab) 213

Ketoacidosis, therapy of diabetic-induced, 135

Kimble, Mary Ann (author) *The Sleeping Women*, 153

Klainer, Albert S. (co-author) *Antineoplastic Agents as a Cause of Fever*, 126

Knowles, Jimmy H. (author) abstracts, 113, 114, 115, 333, 392, 393, 394, 395

Kotabe, Sharonlee E. (co-author) letter giving guidelines for IV compatibility, 155

Koup, Jeffrey R. (co-author) letters concerning use of heparin and gentamicin, 338, 568; letter concerning variable heparin strengths, 387

Kreider, Lloyd A. (author) letter commenting on prescription renewal article, 666

Kresel, James J. (author) letter commenting on tartrazine article, 330

L

Laboratory Tests, drug interactions, 26, 536

Lactic Acidosis, phenformin-induced, 236

Lamy, Peter P. (author) *Possible Determinants of the Practice of Pharmacy in the Year 2000*, 426; (co-author) *Technical and Theoretical Aspects of Patient Counseling Using Audiovisual Aids*, 485

Lauper, R. David (co-editor) *Drug Evaluation Data*, 42

Laventurier, Marc (co-author) *PSRO-Participation Pathways for Pharmacists*, 553

Law, and clinical pharmacy, 124; prescription renewals, 489; temporary state licensure for pharmacy residents (ed) 97

Letters to the Editor

AIHP, pharmacy bicentennial speakers, 570

antacids, for decubitus ulcers, 54

antibiotic utilization, 155

ASHP, new goals for, 101

bacterial meningitis, 457; author's response, 457

benzyl alcohol, toxicity of, 154

bioavailability, evaluating, 55

clinical pharmacist group practice article, omission of acknowledgement, 54

clinical pharmacology-pharmacy seminar, 276

clinical pharmacy, dilemma of, 54; possible solution to, 55; vs. traditional practice, 329, 568

chloroquin, intestinal amebiasis, 569

community pharmacist, vital professional, 618

community pharmacy practice in the year 2000, 621

computers, patient monitoring, 516

cost effectiveness comparisons, 517; author's reply, 518

darvon, positive results for methadone screening, 515

decubitus ulcers, antacids for, 54

degrees, B.S. and Pharm.D., 569; professional, and deans, 330, 515; vs. self-education, 100

DICP and community practitioners, 207

dioxin, error in December 1974 article, 154; error in peptic ulcer case study, 274

Diodoquinol, intestinal amebiasis, 569

diphenylhydantoin dosage, 274

dopamine for shock therapy, 456, 665

drugs and hyperbaric oxygen, 276

education, continuing, 276; list of Pharm.D. programs, 207; open university in Tennessee, 101

emetine, intestinal amebiasis, 569

family practitioner article, omission of acknowledgement, 54

five-year Pharm.D., 619; editor's response, 620

gentamicin, overdosage, 618; reduction in heparin activity, 568

glue, fast-drying, hazards of, 515

heparin, gentamicin, in peritoneal dialysis solutions, 388; reduction in activity by gentamicin, 568; variable strengths, 387

hospital prescription blanks, use of, 54

humorous poem about Paul de Haen's cards, 567; de Haen replies, 664

hyperbaric oxygen, interaction with drugs, 276

inderal, adverse reaction, 455

insulin adsorption in protein solutions, 664

intestinal amebiasis, 569

IV compatibility, guidelines for, 155

Jelliffe's computer program, patient monitoring, 516

lidocaine in myocardial infarction, 275

meningitis, bacterial, 457; author's response, 457

metronidazole, intestinal amebiasis, 569

my son, the clinical pharmacist, 457

open university in Tennessee, 101

patient information, 665

patient oriented pharmacy practice, 328; author's response, 329

peptic ulcer case study, 386, author's response, 387

pharmacy, manuals, 54; quest for professional direction, 206; in the Soviet Union, 154; temporary licensure for residents, 274; women's roles, 516

polyvinyl chloride plastics, IV use, 518

practical drug therapy '75, continuing education course, 276

prescription blanks, use of, 54

prescription renewals, reader comment and author response, 666-668

professional degrees, and deans, 330, 515; vs. self-education, 100

residents, pharmacy, temporary state licensure, 274

self-education vs. professional degrees, 100

tartrazine article, additional information, 568; author's addendum, 330; praise for, 330

tetracycline, intestinal amebiasis, 569

Levodopa, interaction with papaverine (ab) 214

Lewis, Marlane C. (co-author) *The Use of Computers in Pharmacy in the Year 2000*, 439

Licensure, temporary, for pharmacy residents (ed) 97, (letter) 275

Lidocaine (ab) 215; in myocardial infarction (letter) 275

Lipexal, investigational drug information, 656

Literature, 102, 210, 389, 460, 522, 572; adverse drug reactions, 190; professional, and the pharmacist (ed) 513

Lithium, 536; flu-like syndrome (ab) 332; heart failure (ab) 163; multifocal myoclonus (ab) 332; therapy, 17

Lithium Carbonate, haloperidol, irreversible brain damage (ab) 58

Lithocholate, metabolism (ab) 671

Lomolif, overdose (ab) 114

Lovett, Larry T. (author) letter concerning drugs and hyperbaric oxygen, 276

Lukasiewicz, Ronald (author) letter concerning hazards of fast-drying glues, 515

Lunan, Hugh N. (ed) *Drug-Drug Interactions*, 269; *New Developments in Pharmacy - How Does the Institution Meet This Need?*, 453

Lupus-like Syndrome, drug induced (ab) 278

Mc

McCarron, Margaret M. (author) *An Approach to Clinical Pharmacy*, 12; *A System of Inpatient Drug Monitoring*, 80; *Management of Severe Diabetic Ketoacidosis*, 135

McCart, Gary (co-editor) *The DIAS Rounds*, 190

McClain, P. R. (co-author) *Isolation, Propagation, Freeze Preservation and Studies of Drug*

Sensitivity of *Toxoplasma gondii* in Human Tissue Culture, 264
McCoy, Linda K. (author) abstracts, 392, 464, 465
McEvilla, Joseph D. (co-author) The Use of Computers in Pharmacy in the Year 2000, 439
McKercher, Patrick L. (author) letter concerning continuing education course, 276
McLeod, Don C. (author) Pharmacy Practice in the Year 2000, 406; Structuring Clinical Pharmacy Residencies to Provide Future Patient Drug Therapy Needs, 606; (ed) The Dilemma in Pharmacy Residency Training, 382; Drug Evaluation Data, 42, 361, 501, 577; Strategy for Clinical Pharmacy in Hard Times, 204
McMahon, F. Gilbert (author) letter praising "My Son, the Clinical Pharmacist," 457

M

Mandrax Overdose, peripheral neuropathy (ab) 577
Manzani, Ronald (author) letter on Jelliffe's computer program, patient monitoring, 516
Marek, Donald (author) letter concerning dopamine for shock therapy, 458
Marketing Rating of Drugs, 144
Martin, L. Robert (author) letter about family practitioner - group practice article, 54
Medication Instructions, patient compliance (ed) 268
Medical Staff, and formulary revision, 596
Melphalan, comparison in myeloma (ab) 216; myelomonocytic leukemia (ab) 214
Meningitis, bacterial, case study, 422, comment and author response (letters) 547; cryptococcal, flucytosine, 180
Meprobamate, death (ab) 393; interactions, 26; malformations (ab) 393
Mesoridazine, absorption and excretion (ab) 280
Methadone, results of births to patients on (ab) 216; withdrawal, fetal stress (ab) 465; withdrawal in neonates (ab) 528
Methadone Hydrochloride, withdrawal symptoms (ab) 214
Methaqualone, overdose, peripheral neuropathy (ab) 577
Methotrexate, distribution in cerebrospinal fluid (ab) 578
Methyldopa, hemolytic anemia (ab) 277; interaction with thiazide (ab) 577; metabolism (ab) 114
Methylprednisolone, anaphylactic reaction (ab) 331
Metronidazole, bacteroides infections (ab) 279; intestinal amebiasis (letter) 569
Michocki, Robert J. (author) letter concerning peptic ulcer case study, 386
Miconazole, for candidoidomycosis (ab) 59
Miller, Richard Y. (author) letter concerning hospital prescription blanks, 54
Miller, William A. (author) book review, 460
Minoxidil, interaction with propranolol (ab) 162; pharmacodynamics of (ab) 578
Mitchell, John F. (author) letter concerning the hazards of fast-drying glues, 515
Morphine, interaction with gallamine (ab) 277; with pancuronium (ab) 277; with propranolol (ab) 277
Morris, Raymond W. (co-author) Technical and Theoretical Aspects of Patient Counseling Using Audiovisual Aids, 485
Motrin, evaluation, 501
Mrtek, Robert G. (author) letter concerning AIHP, pharmacy bicentennial speakers, 570
Mussalam, N. A. (co-author) Isolation, Propagation, Freeze Preservation and Studies of Drug Sensitivity of *Toxoplasma gondii* in Human Tissue Culture, 264
Nutrition, parenteral, in pediatrics (ab) 625

N

Naloxone, in methadone poisoning (ab) 529
Neisseria Meningitidis, case study, 242
Nelson, Arthur A., Jr. (co-author) An Evaluation of the Quality of Pharmaceutical Care: A Study of the Pharmacist's Compounding Behavior, 591
New Drugs 1973/1974, 504
New Drugs, time of marketing, 144; 504
New Products Parade, 504
Nipride, See Sodium Nitroprusside
Nitrofurantoin, hepatic injury (ab) 278
Nitroglycerin, Sodium, evaluation, 361
Nitrous Oxide, interaction with gallamine (ab) 277, with pancuronium (ab) 277
Nona, Daniel A. (author) list of Pharm.D. programs (letter) 207
Nortriptyline, interaction with alcohol (ab) 527
Norwood, G. Joseph (author) Impact of a Clinical Pharmacist's Emphasis on Patient Communication on the Patient's Attitude Toward Pharmacy, 601
Novobiocin-Tetracycline, pseudomembranous colitis (ab) 278
Nurses, interdisciplinary practice, 420; education, 80; roles, 648

Nurse Practitioner, management of patients with diabetes mellitus (ab) 222
Nursing Homes, prescribing in, 365

O

Oral Contraceptives, breast cancer (ab) 464; death from myocardial infarction (ab) 528; effects on plasma vitamins, cholesterol and triglycerides (ab) 670; intracranial venous thrombosis (ab) 163; myocardial infarction (ab) 527; stroke (ab) 393
Orphenadrine, interaction with chlorpromazine (ab) 623
Oxygen Anesthesia, interaction with gallamine (ab) 277, with pancuronium (ab) 277
Oxymetholone, perturbations of menstrual cycle by (ab) 217

P

Pain, operant conditioning program, 68
Pancuronium, interaction with morphine (ab) 277, with nitrous oxide (ab) 277, with oxygen anesthesia (ab) 277, with tubocurarine (ab) 277
Papaverine, interaction with levodopa (ab) 214
Parenteral Hyperalimentation, 493; in pediatrics (ab) 625
Patents, 504
Patient, attitude toward pharmacy, 601; compliance (ed) 268; conditioning against chronic pain, 68; counseling, 480, 485; drug therapy needs, 606; education, 601; information (letter) 665; medication history, 80; oriented pharmacy practice (ed) 151, (letter) 328, author response, 329
Pediatric Case Studies, Bacterial Meningitis, 242; Pneumocystis Carinii Pneumonia, 657
Peptic Ulcer, case study, 86
Pelligrino, Edmund D. (author) Meddlesome Medicine and Rational Therapeutics, 480
D-Penicillamine, Goodpasture's Syndrome (ab) 464
Penicillin, hemolytic anemia (ab) 277, 577; pseudomembranous colitis (ab) 278
Pentamidine, in pneumocystis carinii pneumonia, 657
Pentazocine, comparison with fentanyl (ab) 529
Peptic Ulcer, case study, 86; letter of comment, 386; author response, 387
Perry, Paul J. (co-author) Activities of the Clinical Pharmacist Practicing in the Office of a Family Practitioner, 129; letter about family practitioner - group practice article, 54
Personnel Placement, 171, 227, 282, 339, 468, 530, 531, 575, 576, 626, 627, 628, 672, 673
Pharmaceutical Care, evaluation of quality of, 591
Pharmacogenetics, new research (ab) 279
Pharmacokinetics, 501; data needed in diseased individuals (ed) 270; drug interactions, 536; drug interactions, antianxiety drugs, 26; flucytosine, 180; ibuprofen, 501; lithium, 17; See also Biopharmaceutics
Pharmacy manuals, data for (letter) 54
nursing, interdisciplinary practice, 426
practice, 480; community (ed) 514; in year 2000 (ed) 454; new developments in (ed) 453; private practitioner (ed) 512; quality of, 591; responsibility of (ed) 383
professional standards review, 292, 553
quest for professional direction (ed) 45, (letter) 206
residents, temporary state licensure (ed) 97, (letter) 275; training, 606, (ed) 382
roles, drug advisor to patients (ab) 159; in formulary revision, 596; future, 426
service, 553; patient education (ed) 322; who needs it? (ed) 323
Soviet Union, impressions of (letter) 154
supportive personnel, 434; education and utilization (ed) 452; future roles, 430; future use, 406
women in (ed) 663
Pharmacy & Therapeutics Committee, formulary revision, 596
Pharm.D. Programs, five-year (ed) 384, letter, 619, editorial response, 620; guidelines for (ed) 617; list of (letter) 207
Phenacetin, renal disease (ab) 331
Phenformin, induced lactic acidosis, 236; and vitamin B₁₂ deficiency (ab) 162
Phenobarbital, interaction with chlorpromazine (ab) 623; with hepatic drug metabolizing enzymes (ab) 623; with vitamin D (ab) 670
Phenothiazines, and benzotropine, fatal paralytic ileus (ab) 465; interactions, 536
l-Phenylalanine Mustard, in breast cancer (ab) 280
Phenytoin, kinetics and protein binding (ab) 578
Phlebitis, 76
Physicians, and clinical pharmacy, 129; education, 80; orders, evaluation, 80; role in formulary revision, 596
Pickard, Ann S. (co-author) The Effect of In-

Line Final Filtration on Occurrence of Phlebitis, 76
Pierpaoli, Paul G. (ed) The Rise and Fall of Clinical Pharmacy Education, 97
Pietrusko, Robert G. (ed) Clinical Pharmacy Service - Who Needs It?, 323
Placebo, interaction with alcohol (ab) 527
Pluhar, Robert E. (author) book review, 103
Pneumocystis Carinii Pneumonia, pediatric case report, 657
Pneumonia, treated with pentamidine, 657
Poem, humorous, about Paul de Haen's cards (letters) 567, 664
Poisoning, by salicylates, 350
Polyvinyl Chloride Plastics, IV use (letter) 518
Popovich, Nicholas G. (co-author) Potential Drug Interactions - Fact or Fallacy?, 586
Population, fertility control (ab) 232; growth, 36; and the quality of life (ed) 46
Porter, L. Kent (ed) The Literature and the Pharmacist, 513
Porter, R. Stephen (co-author) letter giving possible solution to dilemma of clinical pharmacy
Potassium Citrate, interaction with calcium gluconate (ab) 466
Potassium Iodide, cardiac irritability (ab) 113
Practolol, effects on plasma-lipids (ab) 279
Pregnancy, *Toxoplasma gondii*, 264
Prescribing, of drugs, 365; sociology of (ab) 156; rational, 480
Prescription, blanks, hospital (letter) 54; generic and brand name costs (ab) 222; ingredient costs (ab) 158; renewals, legal aspects, 489, comment on article and author response (letters) 666-668
Prince, Randall A. (co-author) Antineoplastic Agents as a Cause of Fever, 126; (ed) The Need for Pharmacokinetic Data in Diseased Individuals, 270
Professional Degrees and Deans (ed) 205, (letters) 330, 515
Professional Organizations, future roles, 426
Professional Standards Review, 292; participation pathways for pharmacists, 553
Progestogen, injectable long-acting contraception (ab) 333
Propoxyphene, overdose (ab) 113
Proparolol, interaction with minoxidil (ab) 162; interaction with morphine (ab) 277; intractable arrhythmias controlled by (ab) 394; kinetics in renal disease (ab) 59; treatment of thyrotoxicosis (ab) 215; treatment of hypertension (ab) 335
Propylthiouracil, liver disease (ab) 215
Prostaglandin E₂, bronchodilation (ab) 529; intrauterine death treated with (ab) 334
Prostaglandin F₂ Alpha, bronchoconstriction (ab) 529; pregnancy termination (ab) 331
Pseudoephedrine, interaction with triprolidine (ab) 213
Psychotherapeutic Drug Interactions, antianxiety drugs, 26; antipsychotic drugs, 536

Q

Quality of Pharmacy Practice, 591
Quinidine, hemolytic anemia (ab) 277
Quiz, antipsychotic drugs, 536; parenteral hyperalimentation, 493

R

Raleigh, Fred (author) letter concerning adverse reaction to Inderal, 455
Rapp, Robert P. (co-author) A Self-Instructional Learning Package About Parenteral Hyperalimentation for Students of Nursing, Pharmacy and Medicine, 493; (ed) Patient Oriented Pharmacy Practice - Does it Include Traditional Services?, 151; letter responding to comments on editorial, 329
Referees for 1975, 674
Rehder, Terry L. (author) abstracts, 185, 214, 215; book review, 523
Reinders, Thomas P. (ed) Patient Education - A Clinical Pharmacy Service, 322
Reinhart, James L. (author) letter concerning bacterial meningitis article, 457
Renal Failure, cefazolin kinetics (ab) 670; reaction to sulfamethoxazole, 660
Research, clinical (ed) 324; compounding accuracy, 591; in drug abuse, 370; new drugs, 504
Residents, Pharmacy, temporary state licensure (ed) 97, (letter) 275; training, 606; (ed) 382
Rifampin, interaction with warfarin (ab) 466
Robayo, Juan Rodriguez (author) letter commenting on editorial, 330
Robertson, Joel C. (co-author) letter giving possible solution to dilemma of clinical pharmacy, 55
Roffman, David S. (author) letter on peptic ulcer case study, 386
Role Models, scarcity for clinical pharmacists, 12
Romankiewicz, John A. (ed) Spanning the Gap - Clinical Research, 324
Rounds, hospital, pharmacist's role (ed) 270

Rucker, T. Donald (author) PSRO: Current Issues - Future Trends, 292
 Rupp, Claudia A. (co-author) letter giving guidelines for IV compatibility, 155

S

Salicylates, intoxication, 350; kinetics of in children (ab) 333; percutaneous absorption (ab) 624; See also Aspirin
 Schneiweiss, Fred (author) letter on clinical vs. traditional pharmacy practice, 329
 Schooff, Kenneth C. (co-author) Pharmacy Involvement - Polydrug Detoxification Unit, 638
 Schwartz, Michael A. (author) Educational Needs for Pharmacy Practice in the Year 2000, 447; letter concerning B.S. and Pharm.D. degrees, 569
 Searcy, Donald M. (co-author) The Effect of In-Line Final Filtration on Occurrence of Phlebitis, 76
 Self, Timothy H. (co-author) Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole, 660
 Self-Education, vs. professional degrees (letter) 100
 Self-Instruction, parenteral hyperalimentation, 493
 Serum Levels, digoxin (letter) 274; monitoring, lithium therapy, 17
 Shearer, Cameron A. (author) abstracts, 165, 213, 215, 216, 217, 278, 332, 333, 334, 465, 528, 529
 Shimomura, Sanae K. (co-author) Adverse Drug Reactions, 190; (co-editor) The DIAS Rounds, 190
 Siler, W. A. (author) letter concerning self-education, 100
 Silkaitis, Raymond P. (author) letter on pharmacy in the Soviet Union, 154
 Silver Sulfadiazine, evaluation of (ab) 59
 Slingert, James R., Jr. (author) book review, 104
 Sittler, Lynne (co-author) The Impact of the Pharmacy Technologist Upon Pharmacy Practice in the Year 2000, 434
 Slining, Judith M. (author) Women's Role in Pharmacy Practice in the Year 2000, 415
 Smith, Dorothy L. (ed) Why Should Patients Comply With Medication Instructions?, 268
 Sociology, of prescribing (ab) 156
 Sodium Cromoglycate, in PGF α -induced bronchoconstriction (ab) 529
 Sodium Nitroprusside, evaluation data, 361
 Sodium Warfarin, ecchymosis (ab) 392; See also Warfarin
 Solutions, filtration, 76
 Spironolactone, interaction in urinary acidification (ab) 57
 Standards, professional review, 292, 553
 State Licensure, temporary, for pharmacy residents (ed) 97, (letter) 275
 Steiner, Gilbert A. (co-author) Pharmacy Involvement - Polydrug Detoxification Unit, 638
 Steroids, peliosis hepatis (ab) 114
 Stewart, Ronald B. (ed) The Fatal Drug-Reaction Debate, 382; What the Pharmacist Needs to Know, 664
 St. Onge, George D. (author) letter concerning DICP and community practitioners, 207
 Students, women, 413
 Stulberg, Cyril (co-author) Isolation, Propagation, Freeze Preservation and Studies of Drug Sensitivity of *Toxoplasma gondii* in Human Tissue Culture, 264
 Succinylcholine, hypoventilation (ab) 214
 Sulfadiazine, silver, evaluation of (ab) 59
 Sulfamethoxazole, adverse reaction, 660
 Sulfaphenazole, interaction with cyclophosphamide (ab) 624
 Sulfonamides, adverse effects, 190
 Sulfisoxazole, and chronic granulomatous disease (ab) 395
 Summerfield, Marc R. (author) book review, 389
 Supportive Personnel, See Pharmacy Supportive Personnel
 Swanson, Larry N. (co-author) Pharmacy Involvement - Polydrug Detoxification Unit, 638
 Swift, Robert G., Jr. (co-author) The Effect of In-Line Final Filtration on Occurrence of Phlebitis, 76

T

Tannic acid, hepatotoxicity (ab) 115
 Tartrazine containing drug products, 198, (letters) 330, 568
 Technicians, in the year 2000, 430; See also Pharmacy Supportive Personnel
 Technologist, pharmacy, 434; See also Pharmacy Supportive Personnel
 Temple, Thomas R. (co-author) An Evaluation of the Quality of Pharmaceutical Care: A Study of the Pharmacist's Compounding Behavior, 591

Tests, on antipsychotic drugs, 536; on parenteral hyperalimentation, 493
 Tetracycline, intestinal amebiasis (letter) 569
 Theophylline, interaction with ephedrine (ab) 527, with hydroxyzine (ab) 527
 Thiazide, interaction with methyldopa (ab) 577; pancreatitis, 190
 Thioridazine, absorption and excretion (ab) 280; alternative to diazepam (ab) 335; interaction with alcohol (ab) 623, with chlordiazepoxide (ab) 623, with diazepam (ab) 623
 Thiothixene, hyponatremia (ab) 279
 Thompson, Gregory A. (author) Peptic Ulcer, 86; letter correcting typographical error in article, 274; letter responding to comments on article, 386
 Three-dihydroxyphenylserine, investigational drug, 655
 Thymoxamine, in PGF α -induced bronchoconstriction (ab) 529
 Tobias, Dianne E. (ed) Round and Round, 321; letter about peptic ulcer case study, 386
 Tolbutamide, isotropic effects (ab) 214
 Torricci, Michael P. (author) letter about darvon and methadone screening, 515
 Tourville, John (author) Sodium Nitroprusside Evaluation, 361
 Toxoplasma gondii, drug sensitivity, 264
 Toxoplasmosis, drug sensitivity, 264
 Traffic Accidents, and drugs, 370
 Tranlycypromine, isomers (ab) 115
 Triglycerides, plasma, effect of oral contraceptives (ab) 670
 Trimethadione, adverse reaction (ab) 669
 Triprolidine, interaction with pseudoephedrine (ab) 213
 Tse, Teddy C. S. (author) abstracts, 57, 113, 115, 162, 163, 331
 Tubocurarine, interaction with gallamine (ab) 277, with pancuronium (ab) 277

U

Urinary Acidification, effect of spironolactone (ab) 57

V

Vance, John W. (author) letter concerning variable heparin strengths, 387
 Varano, Carmine Raymond (author) letters: concerning women's roles in pharmacy, 516; temporary licensure for pharmacy residents, 274; patient information, 655
 Viloxazine Hydrochloride, blood level studies (ab) 625
 Vincristine, increased secretion of ADH (ab) 394
 Vinyl-chloride, liver disease (ab) 278
 Vitamin B $_{12}$, interaction with phenformin (ab) 162; malabsorption (ab) 466
 Vitamin D, interaction with phenobarbital (ab) 670
 Vitamin E, coagulopathy (ab) 58
 Vitamins, and oral contraceptives (ab) 216; plasma, effect of oral contraceptives (ab) 670

W

Warfarin, hemorrhage-breast necrosis (ab) 392; interaction with ethacrynic acid (ab) 213; with rifampin (ab) 466; sodium, ecchymosis (ab) 392
 Watanabe, Arthur S. (co-author) Adverse Drug Reactions, 190
 Weber, Charles E. (author) letter praising editorial, 621
 Weinstein, William M. (author) letter concerning term "doctor of pharmacy," 618
 Weishurst, Mark (co-author) Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole, 660
 Wells, Peter G. (author) letter about patient oriented pharmacy practice editorial, 328
 Wentz, Margaret R. (author) letter requesting data for pharmacy manuals, 54
 West, Sheila (author) Women in Pharmacy - Some Predictions for Women Students and Faculty, 412
 White, Eugene V. (author) Prescription Renewals - The Pharmacist's Dilemma, 489; letter responding to comments on article, 667
 Whitney, Harvey A. K., Jr. (ed) Educating the Public about Drugs, 571; The Education and Utilization of Pharmacy Supportive Personnel, 452; The Five-Year Pharm.D., 384; (co-author) The Impact of the Pharmacy Technologist Upon Pharmacy Practice in the Year 2000, 434; (author) book review, 103
 WHO Expert Committee on Drug Dependence, 249, 300, 370
 Winship, Henry W., III (co-author) A Cost Effectiveness Comparison of a Pharmacist Using Three Methods for Identifying Possible Drug Related Problems, 257
 Women in Pharmacy, 153; future roles, 412; as practitioners in 2000, 415; roles (letter) 516; salute to (ed) 663
 Wood, George C. (co-author) A Cost Effectiveness Comparison of a Pharmacist Using

Three Methods for Identifying Possible Drug Related Problems, 257
 World Health Organization Report, Drug Dependence, Part I, 249; Part II, 300; Part III, 370
 World Population Conference, 36

X-Y-Z

Zilz, David (author) Total Medical Staff Participation in Formulary Revision, 596

ADVERTISERS

Abbott Laboratories
 Abbo-Pac® Unit Dose, Ja-8-9, F-66-67
 ADIS Press, D-628
 American Institute of the History of Pharmacy
 Membership Information, F-63, S-473
 American Society of Hospital Pharmacists
Drugs in Health Care, S-471, D-636; *International Pharmaceutical Abstracts*, Ma-231, S-475, D-637
 Paul de Haen, Inc.
 Three new indices, Ap-189, Ma-276
 Drug Intelligence & Clinical Pharmacy, Inc.
 Subscription Information, Ja-1fc, F-1fc, Mr-1fc, Ap-1fc, Ma-1fc, Ju-1fc, Jl-1fc, Ag-1fc, S-1fc, O-1fc, N-1fc
 Drug Intelligence Publications, Inc.
 Books and Tapes available, Ja-48, 49, 52, 53, F-106-109, Mr-166-169, Ap-218-221, Ma-256-257, Ju-312-313, Ag-432-433, S-479, S, O, N-center inserts
 Clinical Pharmacy Handbook for Patient Counseling, Ag-459, S-525, N-1fc, D-628
 Fate of Drugs in the Organism, Ja-51, Ap-1bc
 Fundamentals of Clinical Pharmacokinetics, Ju-326-327, Jl-390-391, Ag-462-463, S-520-521, D-634-635
 Fundamentals of Medications, 2nd ed., Ja-1bc, Mr-119, Ap-179, Ju-1bc, D-634-635
 Guide to Drug Information, Ma-235, Ju-325, Ag-405
 Handbook of Basic Pharmacokinetics, Ju-338, Ag-433, S-500
 Handbook of Clinical Drug Data, Ap-175, Ma-284, Ju-337, Jl-369, Ag-458
 Handbook of Drug Interactions, Ma-281
 Handbooks of IV Additive Reviews, Ja-7
 I.V. Additive Reviews, Ma-24
 Index Nominum, Ag-467, S-524
 Laboratory Manual of Biopharmaceutics and Pharmacokinetics, F-110, Mr-170, Ap-226
 Organic Medicaments and Their Synonyms, Mr-123, Ju-287
 Principles of Clinical Pharmacy Illustrated by Clinical Case Studies, Ja-50, F-111, Mr-134, Ma-262, Ju-336
 USAN 10, Ja-10-11, F-64-65, Ap-224-225
 USAN 1975, D-632-633
 Eli Lilly and Co.
 Keflex®, Ja-3, F-1bc, Mr-1bc, Ap-1bc
 Keflin® I.V., Ma-1bc, Ju-1bc, Jl-1bc, Ag-1bc
 Kefzol® I.V., S-1bc, O-1bc, N-584, D-1bc
 Merrell-National Laboratories
 Bentyl®, Ja-1bc, F-1bc, Jl-349, S-472, N-605
 Personnel Placement, Mr-171, Ap-227, Ma-282, Ju-339, Ag-468, S-530-531, O-575-576, N-626-627-628, D-656, 672-673
 Pharmacia, Inc.
 In the Fight Against Phlebitis, Jl-1bc
 Larson Filter Pin, O-1bc, N-1bc
 Larson Safety Caps and Larson Filter Pin, Ag-1bc, S-1bc
 UFO, D-1bc
 Rhode Island Hospital and University of Rhode Island
 Joint Position available, F-101
 Roche Laboratories, Inc.
 Hospital Pharmacy Program, Mr-160-161, Ap-208-209
 The Roche Hospital Pharmacy Advisory Board, Ju-290-291, Jl-344, Ag-400-401
 Valium®, Mr-120-122, Ap-176-178, Ma-232-234-272-273
 Valium® Quiz, Ja-4-6, Jl-346-347, S-476-478
 Valium Tel-E-Dose, Ag-402-404
 Smith Kline & French Laboratories
 Preparation, Ag-399, S-474, O-535, N-585
 Single Unit Packages, N-583, D-631
 E. R. Squibb & Sons, Inc.
 When the choice is yours . . . , Mr-1bc, Jl-343
 When the Decision is Yours, Ma-1bc
 University of California, San Francisco
 Clinical Pharmacy Teaching Service Position, F-99, Ag-446
 University of Cincinnati
 Biopharmaceutics Correspondence Course, S-526
 University of Massachusetts Medical Center
 Senior Clinical Pharmacist, Ja-60
 University of Missouri at Kansas City
 Faculty Positions, Clinical Pharmacy and Drug Information, F-99
 University of Southern California
 Announcement of residencies, Ja-56
 World Population Society
 Membership Information, Ja-41
 Guild of Hospital Pharmacists, S-532

